EA202092955A1 - Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза - Google Patents

Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза

Info

Publication number
EA202092955A1
EA202092955A1 EA202092955A EA202092955A EA202092955A1 EA 202092955 A1 EA202092955 A1 EA 202092955A1 EA 202092955 A EA202092955 A EA 202092955A EA 202092955 A EA202092955 A EA 202092955A EA 202092955 A1 EA202092955 A1 EA 202092955A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alcoxy
fibrosis
antagonists
treatment
application
Prior art date
Application number
EA202092955A
Other languages
English (en)
Inventor
Мартин Болли
Кристина Брочи
Сириль Леско
Джоди Т. Уильямс
Original Assignee
Идорсия Фармасьютиклз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Идорсия Фармасьютиклз Лтд filed Critical Идорсия Фармасьютиклз Лтд
Publication of EA202092955A1 publication Critical patent/EA202092955A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Изобретение относится к пиридинильным производным формулы (I)где R1, R2, R3, R4, R5, R6, Ar1, L, W, Z, m и n являются такими, как указано в описании, их получению, к их фармацевтически приемлемым солям и к их применению в качестве лекарственных средств, к фармацевтическим композициям, содержащим одно или несколько соединений формулы (I), и в особенности к их применению в качестве модуляторов рецепторов LPA1.
EA202092955A 2018-06-07 2019-06-05 Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза EA202092955A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018065016 2018-06-07
PCT/EP2019/064690 WO2019234115A1 (en) 2018-06-07 2019-06-05 Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis

Publications (1)

Publication Number Publication Date
EA202092955A1 true EA202092955A1 (ru) 2021-04-08

Family

ID=66912779

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092955A EA202092955A1 (ru) 2018-06-07 2019-06-05 Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза

Country Status (22)

Country Link
US (1) US20210246116A1 (ru)
EP (1) EP3802517B1 (ru)
JP (1) JP7386183B2 (ru)
KR (1) KR20210018900A (ru)
CN (1) CN112236424B (ru)
AU (1) AU2019282274A1 (ru)
BR (1) BR112020024879A2 (ru)
CA (1) CA3102683A1 (ru)
DK (1) DK3802517T3 (ru)
EA (1) EA202092955A1 (ru)
ES (1) ES2940695T3 (ru)
FI (1) FI3802517T3 (ru)
HR (1) HRP20230243T1 (ru)
HU (1) HUE061559T2 (ru)
LT (1) LT3802517T (ru)
MX (1) MX2020013291A (ru)
PL (1) PL3802517T3 (ru)
PT (1) PT3802517T (ru)
RS (1) RS63990B1 (ru)
SI (1) SI3802517T1 (ru)
TW (1) TW202016090A (ru)
WO (1) WO2019234115A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214119A1 (en) 2022-05-05 2023-11-09 Equinorm Ltd Azetidine compounds, pharmaceutical compositions thereof, preparation methods and their uses in the treatment of cns disorders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
MX2022006736A (es) 2019-12-04 2022-07-11 Idorsia Pharmaceuticals Ltd Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US20070078120A1 (en) 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
BRPI0416708A (pt) 2003-11-18 2007-01-16 Warner Lambert Co derivados de aminoquinazolidinadiona antibacterianos
BRPI0616799B8 (pt) 2005-08-24 2021-05-25 Eisai R&D Man Co Ltd derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
JP2011500678A (ja) 2007-10-18 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション キノリジノンｍ１受容体ポジティブアロステリックモジュレーター
SG10201609105YA (en) 2008-05-05 2016-12-29 Sanofi Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
JP5675614B2 (ja) 2008-08-26 2015-02-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のチエノピリミジン
ES2532866T3 (es) * 2009-09-25 2015-04-01 Astellas Pharma Inc. Compuesto amida sustituida
BR112013002871B1 (pt) 2010-08-05 2018-11-21 Zoetis Llc derivados de isoxazolina, seu uso e composição farmacêutica ou veterinária
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為ｍＰＧＥＳ－１抑制物的三環化合物
EP2648726B1 (en) 2010-12-07 2018-04-04 Amira Pharmaceuticals, Inc. Polycyclic lpa1 antagonist and uses thereof
HUE029810T2 (en) 2011-03-10 2017-03-28 Zoetis Services Llc Spirocyclic isoxazole derivatives as antiparasitic agents
KR20140107539A (ko) 2011-12-21 2014-09-04 알데릭스, 인코포레이티드 비-전신성 tgr5 작용제
US9650358B2 (en) * 2013-03-13 2017-05-16 Abbvie Inc. Pyridine CDK9 kinase inhibitors
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214119A1 (en) 2022-05-05 2023-11-09 Equinorm Ltd Azetidine compounds, pharmaceutical compositions thereof, preparation methods and their uses in the treatment of cns disorders

Also Published As

Publication number Publication date
SI3802517T1 (sl) 2023-04-28
CN112236424A (zh) 2021-01-15
JP2021527046A (ja) 2021-10-11
ES2940695T3 (es) 2023-05-10
BR112020024879A2 (pt) 2021-03-09
AU2019282274A1 (en) 2021-01-28
CA3102683A1 (en) 2019-12-12
RS63990B1 (sr) 2023-03-31
MX2020013291A (es) 2021-04-29
LT3802517T (lt) 2023-03-10
KR20210018900A (ko) 2021-02-18
EP3802517A1 (en) 2021-04-14
JP7386183B2 (ja) 2023-11-24
PT3802517T (pt) 2023-03-20
CN112236424B (zh) 2024-03-15
FI3802517T3 (fi) 2023-03-23
HRP20230243T1 (hr) 2023-04-14
PL3802517T3 (pl) 2023-05-22
EP3802517B1 (en) 2022-12-21
WO2019234115A1 (en) 2019-12-12
TW202016090A (zh) 2020-05-01
HUE061559T2 (hu) 2023-07-28
US20210246116A1 (en) 2021-08-12
DK3802517T3 (da) 2023-03-13

Similar Documents

Publication Publication Date Title
EA201992679A1 (ru) N-замещенные индольные производные
MD3313849T2 (ro) Noi derivați de hidroxiacid, procedeu de preparare a acestora și compoziții farmaceutice care îi conțin
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
EA201891179A1 (ru) N-замещенные индольные производные в качестве модуляторов pge2 рецепторов
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
EA202092955A1 (ru) Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA202090925A1 (ru) Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
MX2021015727A (es) Derivados de piridin-3-ilo.
NZ775905A (en) Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
MX2020014327A (es) Nuevos derivados de amino-pirimidonilo un proceso para su preparacion y composiciones farmaceuticas que los contienen.